COILED THERAPEUTICS PLC (COIL) — Proposed Oncogeni acquisition and placing

Investor webinar replay

Replay transcript excerpt

Good morning, ladies and gentlemen, welcome to the Rockford Therapeutics PLC Investor Presentation. Throughout this recorded presentation, investors will be in listen only mode. Questions are encouraged. They can be submitted at any time using the Q and A tab situated on the right hand corner of your screen. Please just simply type in your questions and press send. The company may not be in a position to answer every question it receives during the meeting itself. However, the company review all questions submitted today and publish those responses where it's appropriate to do so. Before we begin, we would like to submit the following poll. And if you give that your kind attention, I'm sure the company would be most grateful. And I'd now like to hand over to Executive Chairman, Steve West. Good morning, sir. Thank you. Good morning, everyone. It's a pleasure to be here today to talk about Rockford and specifically our acquisition of Oncogene and the placing, which we announced on Wednesday this week. So we're very excited about it and relishing the opportunity to talk it through with you today. Joining me today is Adjan Reginald, who is gonna be joining the company's CEO. Adjan will be introducing himself a bit later on the presentation, and we'll be talking about Oncogene and the exciting programs Oncogene has. So if we move on just quickly to we'll skip over the disclaimer. Move on to the summary slide. So this sets out I'm not gonna go through this line by line, but it sets out why we're so excited about this acquisition of Oncogene. Essentially, what Oncogene is bringing to us is it's letting us expand our existing portfolio. So we have two drug candidates at the moment. We have an antibody program and oligo RNA program. And Oncogene is bringing in two additional...